Vectura Group (VEC) Ord 0.0271p
Share news, reports & tips
30 November 2020 08:06
(Sharecast News) - Vectura has signed a global licence and development deal with Kinaset Therapeutics of the US for the development and commercialisation of the VR588 pan-JAK asthma treatment.
20 November 2020 08:34
(Sharecast News) - Inhalation-focussed contract design and manufacture organisation Vectura Group announced on Friday that the United States Court of Appeals for the Federal Circuit has denied...
1 May 2020 14:30
(Sharecast News) - Inhalation contract manufacturer Vectura Group noted an announcement from Novartis on Friday, that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use...
13 January 2020 08:25
(Sharecast News) - Pharmaceuticals company Vectura said on Monday that its base business had continued to perform well in 2019.
24 September 2019 12:56
(Sharecast News) - TUI: UBS upgrades to neutral with a target price of 900p.
11 September 2019 13:12
(Sharecast News) - Renew Holdings: Peel Hunt initiates at buy with a target price of 500p.
29 May 2019 14:41
(Sharecast News) - Vectura confirmed on Wednesday that its outlook remains in line with guidance for the full year as it said it was considering returning some capital to shareholders.
29 May 2019 13:44
(Sharecast News) - Serco: RBC Capital Markets upgrades to outperform with a target price of 150p.
24 May 2019 09:29
(Sharecast News) - Vectura Group announced on Friday that it will receive a $2.5m milestone payment under an exclusive licence agreement with Novartis.
3 January 2019 09:44
(Sharecast News) - Vectura Group made gains on Thursday after reporting that it expects full-year underlying earnings to exceed market expectations as the sales performance of its flutiform and Ultibro...
26 November 2018 10:19
(Sharecast News) - Vectura Group announced on Monday that its phase III study of VR475 in adult and adolescent patients with severe uncontrolled asthma did not meet its primary endpoint.
8 November 2018 07:36
(Sharecast News) - Hikma Pharmaceuticals said it was raising group full year guidance after solid performances from its injectibles and generics divisions.
Company announcements Announcements
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2020. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.